ey0015.10-22 | Prevention | ESPEYB15
Writing Committee for the T1DM TrialNet Oral Insulin Study Group
, JP Krischer
, DA Schatz
, B Bundy
, JS Skyler
, CJ Greenbaum
To read the full abstract: JAMA. 2017;318:1891-1902Insulin is one of the autoantigens involved in the pathogenesis of T1DM. Therefore several trials with insulin given orally, nasal or subcutaneous have been conducted to prevent the development of T1DM in genetically high risk populations. This trial design built on the results of DPT-1 and included further investigations related to first phase...